MBNL2

Across TCGA pan-cancer cohorts, MBNL2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MBNL2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MBNL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MBNL2 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

LSCC, COAD, and LUAD are the cancer types where MBNL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.500	0.866	<.001	35	view →
COAD	DFS	Median	III,IV	1.000	0.893	.033	24	view →
LUAD	OS	Tertile	II,III,IV	0.366	0.927	.013	4	view →
PDAC	DFS	Tertile	IV	0.217	0.749	.024	3	view →
UCEC	DFS	Median	All	1.000	0.936	.023	2	view →
HNSC	DFS	Median	II,III,IV	0.911	0.979	.040	2	view →
GBM	OS	Median	All	0.633	0.426	.005	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MBNL2–LSCC (DFS)

Open the LSCC breakdown →